Gilead’s Pill Wins U.S. Panel Backing to Prevent HIV

Gilead Sciences Inc.’s HIV drug Truvada won the backing of a U.S. advisory panel as the first medicine to keep healthy people from getting the virus through sexual activity.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.